nach oben

PharmacoEconomics

Erschienen in:

01.12.2010 | Commentary

Is There A Role For Pharmacoeconomics In Developing Countries?

verfasst von: Dr Zaheer-Ud-Din Babar, Shane Scahill

Erschienen in: PharmacoEconomics | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Excerpt

The special issue of PharmacoEconomics[1] pertaining to developing nations was a welcome move, with authors discussing various themes relating to pharmaceutical economics. The topics discussed included cost-effectiveness analyses and the future of health technology assessment (HTA) in healthcare decision making in the greater Asia region. However, papers in this special issue did not provide an answer to a fundamental question: why is pharmacoeconomics vital for developing countries? Pharmacoeconomics is a complex science and its practical utility depends on the context in which it is being applied. To appreciate the true value of this ‘science’ as a decision-making tool, it is important to elaborate on the context within which healthcare decisions are being made. Furthermore, an understanding of the local health system is also required in order to establish whether complex economic techniques need to be applied and whether they are feasible and valuable tools for a particular jurisdiction. …

Singer ME. Developing nations special issue. Pharmacoeconomics 2009; 27 (11): 887–9PubMedCrossRef

Babigumira JB, Sethi AK, Smyth KA, et al. Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda. Pharmacoeconomics 2009; 27 (11): 963–73PubMedCrossRef

WHO. WHO operational package for assessing, monitoring and evaluating country pharmaceutical situations: guide for coordinators and data collectors [WHO/TCM/2007.2]. Geneva: WHO, 2007 Dec [online]. Available from URL: (http://apps.who.int/medicinedocs/documents/s14877e/s14877e.pdf) [Accessed 2010 Aug 29]

Yang B-M. The future of health technology assessment in healthcare decision making in Asia. Pharmacoeconomics 2009; 27 (11): 891–901PubMedCrossRef

How to develop and implement a national drug policy. 2nd ed. Geneva: WHO, 2001 [online]. Available from URL: (http://apps.who.int/medicinedocs/pdf/s2283e/s2283e.pdf) [Accessed 2010 Aug 28]

Oortwijn W, Mathijssen J, Banta D. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. Health Policy 2010; 95: 174–84PubMedCrossRef

The World Bank. GNI per capita, Atlas method (current US$) [online]. Available from URL: (http://data.worldbank.org/indicator/NY.GNP.PCAP.CD) [Accessed 2010 Aug 26]

WHO. The world medicines situation [WHO/EDM/PAR/2004.5]. Geneva: WHO, 2004 [online]. Available from URL: (http://www.searo.who.int/LinkFiles/Reports_World_Medicines_Situation.pdf) [Accessed 2010 Aug 19]

The World Bank. Health expenditure per capita (current US$) [online]. Available from URL: (http://data.worldbank.org/indicator/SH.XPD.PCAP) [Accessed 2010 Aug 22]

10.

Taiwan: Hutchinson country facts [online]. Available from URL: (http://www.talktalk.co.uk/reference/encyclopaedia/countryfacts/taiwan.html) [Accessed 2010 Jul 7]

11.

Leung GM, Wagstaff A, Lindelow M, et al. The health systems of China, Hong Kong and Taiwan. In: Heggenhougen K, Quah S, editors. International encyclopedia of public health. San Diego (CA): Academic Press, 2008: 656–71CrossRef

12.

Kima HJ, Chungb W, Lee SG. Lessons from Korea’s pharmaceutical policy reform: the separation of medical institutions and pharmacies for outpatient care. Health Policy 2004 June; 68 (3): 267–75

13.

Chou YJ, Yip WC, Lee CH, et al. Impact of separating drug prescribing and dispensing on provider behaviour: Taiwan’s experience. Health Policy Plann 2003; 18 (3): 316–29CrossRef

14.

Laing R. Health and pharmacy systems in developing countries. 2001 Apr 9 [online]. Available from URL: (http://www.wto.org/english/tratop_e/trips_e/hosbjor_presentations_e/05laing_e.pdf) [Accessed 2001 Apr 9]

15.

Kwon S. Pharmaceutical reform and physician strikes in Korea: separation of drug prescribing and dispensing. SocSci Med 2003 Aug; 57 (3): 529–38

16.

Tarn TY-H. Case of Taiwan HTA. Presentation at the 3rd Asia-Pacific ISPOR Conference; 2008 Sep 7-9; Seoul

17.

Kim C. Health technology assessment in South Korea. Int J Technol Assess Health Care 2009; 25 (Suppl. 1): 219–23PubMedCrossRef

18.

Babar ZU, Ibrahim M, Izham M, et al. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med 2007; 4 (3): 466–75CrossRef

19.

WHO, Health Action International. Medicine prices: a new approach to measurement. 2003 ed. [working draft for field testing and revision]. Geneva: WHO, 2003 [online]. Available from URL: (http://whqlibdoc.who.int/hq/2003/WHO_EDM_PAR_2003.2.pdf) [Accessed 2010 Aug 28]

20.

Cheraghali AM. Pharmacoeconomics: an effective tool for prioritization in Iran healthcare system. Iranian J Pharmaceutical Res 2008; 7 (2): 89–91 [online]. Available from URL: (http://www.ijpr-online.com/docs/20082/IJPR606.pdf) [Accessed 2010 Aug 27]

21.

Dinarvand R. New national drug policy in Iran leading to expanded pharmaceutical market and extended access of public to medicines. Iranian J Publ Health 2009; 38 Suppl.1: 158–61 [online]. Available from URL: (http://journals.tums.ac.ir/upload_files/pdf/13390.pdf) [Accessed 2010 Aug 29]

22.

Cheraghali AM. Iran pharmaceutical market. Iranian J Pharmaceutical Res 2006; 1: 1-7 [online]. Available from URL: (http://www.sid.ir/en/VEWSSID/J_pdf/92720060110.pdf) [Accessed 2010 Aug 29 ]

23.

Iranian National Society of PharmEconomics [online]. Available from URL: (http://pharmeconomics.com/) [Accessed 2010 Jul 29]

24.

Iran, medicine prices, affordability and availability. Amsterdam: Health Action International, 2010. (Data on file)

25.

Sultan MSA. How to integrate pharmacoeconomic data in the Middle East countries: the status in Saudi Arabia. Pharmacoeconomics Meeting, Servier International; 2008 Jan 24; Cairo

26.

University Sains Malaysia. Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Pharmacoeconomics, Undergraduate course. Penang [online]. Available from URL: (http://www.usm.my/dsap/undergrad.asp) [Accessed 2010 Aug 24]

27.

Health Action International. Medicine prices, availability, affordability and price components [online]. Available from URL: (http://www.haiweb.org/medicineprices/survey_results.php) [Accessed 2010 Aug 29]

28.

Kingdom of Saudi Arabia. Saudi Food and Drug Authority [online]. Available from URL: (http://www.sfda.gov.sa/En/Drug/Topics/Human_Drugs.htm) [Accessed 2010 Aug 23]

29.

Hameed A. Pharmacoeconomics and outcome research in Pakistan [online]. Available from URL: (http://www.ispor.org/conferences/shanghai0306/pdf/07-Pakistan-Hameed.pdf) [Accessed 2010 Aug 20]

30.

International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Brief definition [online]. Available from URL: (http://www.ispor.org/terminology/default.asp) [Accessed 2010 Sep 20]

31.

The Network for Consumer Protection. Prices, availability and affordability of medicines in Pakistan. Islamabad: The Network for Consumer Protection, 2006 [online]. Available from URL: (http://www.haiweb.org/medicineprices/surveys/200407PK/survey_report.pdf) [Accessed 2010 Aug 19]

32.

WHO, Health Action International. Indonesia: medicine prices, availability and affordability [online]. Available from URL: (http://www.haiweb.org/medicineprices/surveys/200408ID/sdocs/Indonesia-summary-report-FINAL.pdf) [Accessed 2010 Jul 23]

33.

Sooksriwong C, Yoongthong W, Suwattanapreeda S, et al. Medicine prices in Thailand: a result of no medicine pricing policy. Southern Med Review 2009; 2 (2): 10–14 [online]. Available from URL: (http://apps.who.int/medicinedocs/index/assoc/s16381e/s16381e.pdf) [Accessed 2010 Jul 27]

34.

WHO, Health Action International. Philippines: public procurement prices of medicines [online]. Available from URL: (http://www.haiweb.org/medicineprices/surveys/200807PHB/sdocs/zPhilippines-procurement-Final.pdf) [Accessed 2010 Aug 22]

35.

International Health Economics Association (iHEA). Chulalongkorn University: introduction to pharmacoeconomics [online]. Available from URL: (http://www.healtheconomics.org/education/2004/06/chulalongkorn-universityintroducti.html) [Accessed 2010 Aug 26]

Titel: Is There A Role For Pharmacoeconomics In Developing Countries?
verfasst von: Dr Zaheer-Ud-Din Babar
Shane Scahill
Publikationsdatum: 01.12.2010
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 12/2010
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/11584890-000000000-00000

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2010

A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States

The Cost Utility of Autologous Chondrocytes Implantation Using ChondroCelect® in Symptomatic Knee Cartilage Lesions in Belgium

Acknowledgement

Measuring the Externality of Antibacterial Use from Promoting Antimicrobial Resistance

Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices

The Analysis of Multinational Cost-Effectiveness Data for Reimbursement Decisions